Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017 Dec;14(12):e503-e551. doi: 10.1016/j.hrthm.2017.09.001. Epub 2017 Sep 15. Review. PubMed PMID: 28919379.
Habib G, Lancellotti P, Antunes MJ, et al; ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015 Nov 21;36(44):3075-3128. doi: 10.1093/eurheartj/ehv319. Epub 2015 Aug 29. PubMed PMID: 26320109.
Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. doi: 10.1161/CIR.0000000000000296. Epub 2015 Sep 15. Review. Erratum in: Circulation. 2015 Oct 27;132(17):e215. Circulation. 2016 Aug 23;134(8):e113. Circulation. 2018 Jul 31;138(5):e78-e79. PubMed PMID: 26373316.
Habib G, Badano L, Tribouilloy C, et al; European Association of Echocardiography. Recommendations for the practice of echocardiography in infective endocarditis. Eur J Echocardiogr. 2010 Mar;11(2):202-19. doi: 10.1093/ejechocard/jeq004. PubMed PMID: 20223755.
Definition, Etiology, PathogenesisTop
Infective endocarditis (IE) is an infection of the endocardium involving the valves (most frequently), ventricles, atria, or endothelium of vessels in patients with coarctation of the aorta or systemic infection of cardiac implantable electronic devices extending to the electrode leads, valves, or endocardial surface. Most frequently IE affects the mitral and aortic valves; less frequently the tricuspid valve may be involved. IE can involve >1 valve and the proportion of these patients varies in reported literature. IE is preceded by bacteremia, which can last from <2 weeks (80% of patients) to several months (in particular in patients with IE involving a prosthetic valve).
1) Bacteria (>90% of cases). Most frequent pathogens:
a) Staphylococci (an increasingly more common cause of IE; Staphylococcus aureus, Staphylococcus epidermidis, coagulase-negative staphylococci).
b) Streptococci (viridans-group streptococci; until recently the most frequent cause of native valve infections).
d) Gram-negative bacteria, including the HACEK group (Haemophilus spp, Aggregatibacter [formerly Actinobacillus] spp, Cardiobacterium hominis, Eikenella corrodens, and Kingella spp).
e) Mixed bacterial etiology is frequently found among IV drug abusers.
2) Fungi (<1%).
3) Rare: Chlamydia, rickettsia, or mycoplasma.
Depending on criteria definitions for IE, etiology cannot be established in 5% to 20% of patients.
Etiologic agents in patients with negative blood cultures: Culture-negative IE may be seen in the context of antimicrobial use prior to blood cultures being drawn or infections caused by fastidious organisms. These organisms include:
1) Nutritionally variant streptococci.
2) Coxiella burnetii.
3) Bartonella spp.
4) Mycoplasma pneumoniae.
5) Brucella spp.
6) Legionella pneumophila.
7) Fungi (eg, Aspergillus spp).
8) Tropheryma whipplei.
Diseases and conditions predisposing to native valve endocarditis (NVE): Certain heart diseases predisposing to IE are indications for antibiotic prophylaxis (see Prevention, below). Other risk factors include history of rheumatic disease, mitral valve prolapse with regurgitation, hypertrophic cardiomyopathy, valvular or congenital heart disease (particularly affecting the aortic valve, eg, bicuspid aortic valve, coarctation of the aorta), degenerative cardiac lesions, prolonged maintenance of indwelling central venous catheters, foreign bodies in the heart (eg, intracardiac electrodes, vascular patches), chronic hemodialysis, and IV drug use (IVDU) (associated with involvement of right-sided heart valves).
Prosthetic valve endocarditis (PVE) accounts for 10% to 30% of all cases of IE. It most frequently develops within 5 to 6 weeks of surgery. IE occurring within 12 months of surgery is considered a postoperative complication. In the first 2 months after surgery, PVE is most frequently caused by S aureus followed by coagulase-negative staphylococci (mainly methicillin-resistant strains) and Candida spp. In PVE developing >1 year after surgery, etiologic agents are similar to those seen in NVE.
Cardiac device–related infective endocarditis (CDRIE) is most frequently caused by coagulase-negative staphylococci and S aureus.
IE presentation is highly variable and differential diagnosis is often broad, sometimes leading to delay in establishing diagnosis. IE is manifested mainly by nonspecific symptoms, including high-grade fever with chills or prolonged low-grade fever (the most frequent feature), malaise, weakness, arthralgia, myalgia, loss of appetite, weight loss, headache, and nausea.
1. Left-sided endocarditis may also cause symptoms associated with:
1) Regurgitation murmur over the affected valve.
2) Features of heart failure, including pulmonary edema in patients with no prior history of valvular disease.
3) Conduction abnormalities.
4) Rarely large vegetations leading to functional mitral stenosis.
5) Embolic phenomena (most frequently associated with S aureus), including:
a) Central nervous system (CNS) symptoms (30%-40% of patients; hemiparesis, aphasia; behavioral changes in those with microembolism).
b) Rarely intracranial hemorrhage due to ruptured mycotic aneurysm.
c) Renal, splenic, or mesenteric embolism, which may lead to adynamic ileus resulting in abdominal pain or back pain.
d) Coronary artery embolism (rare) manifesting as chest pain.
e) Ocular disturbances associated with retinal artery embolism.
f) Peripheral vascular and inflammation symptoms (petechiae on skin and under nail plates, Osler nodes [painful red nodules located mainly on fingers and toes due to deposition of immune complexes], Janeway lesions [painless hemorrhagic lesions on palms and soles], Roth spots [retinal hemorrhages with pale centers]).
g) Splenomegaly and hepatomegaly (more frequent in patients with long-standing IE).
2) Right-sided endocarditis may also cause symptoms associated with:
1) Pulmonary embolism, with associated cough and pleuritic chest pain (caused by septic pulmonary emboli): This is the most common manifestation.
2) Murmur caused by tricuspid or pulmonary regurgitation: This is often absent or seen in advanced disease.
3) Features of right ventricular failure in patients with long-standing IE.
4) Often recurrent right-sided IE in the case of IVDU, frequently in the absence of other predisposing heart conditions.
Note: IE must always be excluded in patients with embolism and fever.
The following studies should be performed in every patient with suspected IE.
1. Blood cultures (before starting antimicrobial treatment): Obtain ≥3 blood culture sets at 30-minute intervals, regardless of body temperature. Each sample should contain 10 mL of blood collected to an aerobic tube and another 10 mL collected to an anaerobic tube. Mark the order form as suspected IE. In all patients undergoing cardiac surgery, and particularly those with negative results of previous cultures, perform specimen cultures and pathologic examination and, if needed, use molecular identification methods, to identify the etiologic agent.
2. Serologic studies: Perform these in the case of suspected infection with C burnetii, Bartonella spp, Brucella spp, Histoplasma capsulatum, Legionella spp, or Chlamydia spp.
3. Echocardiography: In suspected endocarditis it is important to evaluate for vegetations (mobile echogenic structures attached to the endocardium or intracardiac prosthetic material), valvular damage (regurgitation of the infected valve due to vegetations, leaflet perforation, or rupture of chordae tendineae), and perivalvular complications (abscess, pseudoaneurysm, intracardiac fistula).
In all patients without prosthetic valves with IE suspected on the basis of clinical criteria, transthoracic echocardiography (TTE) should be performed.Evidence 1 Strong recommendation (benefits clearly outweigh downsides; right action for all or almost all patients). High Quality of Evidence (high confidence that we know true effects of the intervention). Mügge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach. J Am Coll Cardiol. 1989 Sep;14(3):631-8. PubMed PMID: 2768712. Lindner JR, Case RA, Dent JM, Abbott RD, Scheld WM, Kaul S. Diagnostic value of echocardiography in suspected endocarditis. An evaluation based on the pretest probability of disease. Circulation. 1996 Feb 15;93(4):730-6. PubMed PMID: 8641002. Habib G, Badano L, Tribouilloy C, et al; European Association of Echocardiography. Recommendations for the practice of echocardiography in infective endocarditis. Eur J Echocardiogr. 2010 Mar;11(2):202-19. doi: 10.1093/ejechocard/jeq004. PubMed PMID: 20223755. Bonzi M, Cernuschi G, Solbiati M, Giusti G, Montano N, Ceriani E. Diagnostic accuracy of transthoracic echocardiography to identify native valve infective endocarditis: a systematic review and meta-analysis. Intern Emerg Med. 2018 Sep;13(6):937-946. doi: 10.1007/s11739-018-1831-0. Epub 2018 Mar 15. PubMed PMID: 29546685. In those with a low clinical probability of IE and a negative TTE result (provided that good-quality images are obtained), IE is unlikely and another diagnosis should be considered. If good-quality TTE images cannot be obtained, transesophageal echocardiography (TEE) should be performed. TEE should be also performed in:
1) Patients with a high clinical probability of IE and a negative TTE result.
2) Patients with suspected IE and a prosthetic valve or intracardiac device.
3) Patients with suspected IE affecting the aortic valve.
4) Patients with IE and significant valvular regurgitation.
5) Patients with a TTE result suggestive of IE (except for those with IE affecting right-sided native heart valves and unequivocal TTE findings). In the case of a negative TEE result and reasonable suspicion of IE, repeat TEE after 5 to 7 days.
Although the mainstay for diagnosis of IE, echocardiography has limitations (it cannot reliably differentiate between active and healed IE, and TTE and TEE sensitivity and specificity are both not 100%). As such, results must be interpreted in the context of clinical presentation.
4. Laboratory tests: There are no biochemical parameters that have been proven to be sensitive or specific for the diagnosis of IE. IE has been associated with elevated erythrocyte sedimentation rate (ESR), increased levels of C-reactive protein (CRP) and fibrinogen, leukocytosis with neutrophilia (most frequent in acute IE), anemia (usually normocytic and normochromic), hematuria, and minor proteinuria.
5. Electrocardiography: Nonspecific findings and conduction abnormalities.
6. Chest radiography: Nonspecific findings, which may include congestive heart failure findings and signs of pulmonary complications.
7. Multislice computed tomography (CT) and magnetic resonance imaging (MRI): CT provides a valuable addition to echocardiography in the diagnosis of perivalvular lesions: abscesses, pseudoaneurysms, and fistulas. It may be also used in patients with prosthetic valves. Multislice CT is useful in the anatomical assessment of the aortic valve (eg, leaflet perforation) and aorta and in the diagnosis of pulmonary embolism in patients with right-side IE, metastatic abscesses (eg, in the spleen), and CNS-related emboli. CT has lower sensitivity than MRI but is more available.
The diagnosis of IE can be made in a patient with sepsis or generalized infection and objective features of endocardial involvement. Relevant diagnostic terminology includes:
1) Definite IE: Table 3.10-1.
2) Possible IE: Table 3.10-1.
3) Active IE:
a) Positive blood cultures or positive intraoperative specimens.
b) Intraoperative confirmation of features of endocarditis.
c) Unfinished course of antimicrobial treatment for IE.
4) Relapse: IE caused by the same microorganism within <6 months of a confirmed episode of IE.
5) Reinfection: IE caused by the same microorganism after >6 months of a previous episode of IE or caused by a different microorganism.
6) CDRIE: CDRIE is difficult to differentiate from local infection of the device. It should be suspected in the case of fever of unknown origin in a patient with a cardiac implantable electronic device. The key diagnostic procedures are echocardiography (TEE has superior sensitivity and specificity but TTE should be performed first) and blood cultures.
Other causes of fever (see Fever of Unknown Origin), systemic connective tissue disease, malignancy, rheumatic fever.
Causes of false-positive echocardiography results: Sterile intracardiac thrombus or tumor resembling vegetations, sterile valvular vegetations (eg, in Libman-Sacks endocarditis in the course of systemic lupus erythematosus, or less frequently in Behçet syndrome, carcinoid, or acute rheumatic fever).
IE requires initial therapy and stabilization of the patient in the hospital. Outpatient parenteral therapy can be considered once this is achieved. Intravenous treatment may vary in duration from 2 weeks (in a highly selective population meeting predefined criteria) up to 4 to 6 weeks (most commonly) or longer.
Treatment of PVE lasts ≥6 weeks. Intravenous treatment is currently recommended, although this may change in the future.
1. Intravenous antibiotics: In acutely ill patients with suspected IE, start empiric treatment immediately after obtaining blood cultures (Figure 3.10-1). The choice of empiric treatment should take into consideration the most likely pathogens. Treatment may be tailored to blood culture results (identified pathogens) and sensitivities once these become available; for instance, streptococcal IE: Figure 3.10-2; staphylococcal IE: Figure 3.10-3; or IE caused by other pathogens (including those causing IE with negative blood cultures): Table 3.10-2.
2. Antithrombotic treatment: Data to guide the use of antithrombotic therapy in the setting of IE are limited, and decisions should be made on a case-by-case basis with consideration given to risks and benefits. IE by itself is not an indication for antithrombotic treatment, but such therapy is generally continued if started previously for other indications in the absence of contraindications. In patients who may need to be qualified for urgent surgery or with international normalized ratio (INR) values showing wide variations, anticoagulation is often switched to unfractionated heparin (UFH). In cases of ischemic or hemorrhagic stroke, all anticoagulants and antiplatelet drugs should be stopped for a minimum of 2 weeks. The optimal length of time for discontinuation is unknown and based on limited evidence. In patients with a prosthetic heart valve and intracerebral hemorrhage, antithrombotic treatment (using UFH) should be resumed as soon as it is safe to do so. In the event of serious hemorrhagic complications, antithrombotic treatment should be stopped, and neurology and hematology service consultations are prudent.
Need for and optimal timing of surgical treatment are among the most difficult therapeutic decisions in the treatment of IE. Surgical intervention may be prompted by hemodynamic instability despite antimicrobial therapy. Decisions regarding surgery should be made by an experienced clinical team with cardiac surgery service and infectious disease consultations and should consider individual risks and benefits.
Indications for emergency surgery (within the first 24 hours): Refractory pulmonary edema or cardiogenic shock caused by severe acute mitral or aortic regurgitation, obstruction, or fistula.Evidence 2 Strong recommendation (benefits clearly outweigh downsides; right action for all or almost all patients). High Quality of Evidence (high confidence that we know true effects of the intervention). Nadji G, Rusinaru D, Rémadi JP, Jeu A, Sorel C, Tribouilloy C. Heart failure in left-sided native valve infective endocarditis: characteristics, prognosis, and results of surgical treatment. Eur J Heart Fail. 2009 Jul;11(7):668-75. doi: 10.1093/eurjhf/hfp077. PubMed PMID: 19553397. Thuny F, Beurtheret S, Mancini J, et al. The timing of surgery influences mortality and morbidity in adults with severe complicated infective endocarditis: a propensity analysis. Eur Heart J. 2011 Aug;32(16):2027-33. doi: 10.1093/eurheartj/ehp089. Epub 2009 Mar 26. PubMed PMID: 19329497. Kiefer T, Park L, Tribouilloy C, et al. Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. JAMA. 2011 Nov 23;306(20):2239-47. doi: 10.1001/jama.2011.1701. PubMed PMID: 22110106; PubMed Central PMCID: PMC5030065.
Indications for urgent surgery in active IE:
1) Symptoms of heart failure or echocardiographic signs of poor hemodynamic tolerance caused by severe regurgitation or obstruction of a native or prosthetic valve.
2) Locally uncontrolled infection with involvement of perivalvular structures (annular or aortic abscess, fistula, leaflet rupture, conduction disturbances).
3) Persistent infection despite appropriate antibiotic treatment: This is defined as persisting bacteremia and fever after 3 to 7 days of antibiotic treatment and exclusion of other causes of persistent positive blood cultures (according to the European Society of Cardiology) or persistent bacteremia or fever for 5 to 7 days in patients in whom other sites of infection have been excluded (according to the American Heart Association).
4) Infection with difficult-to-treat organisms (fungi or multidrug-resistant organisms).
5) PVE endocarditis caused by staphylococci or non-HACEK gram-negative bacteria.
6) Persistent aortic or mitral vegetations >10 mm after ≥1 embolic episode despite appropriate antibiotic treatment (particularly during the first 2 weeks of treatment).
7) Aortic or mitral NVE vegetations >10 mm, associated with severe valve stenosis or regurgitation, and low operative risk.
8) Aortic or mitral NVE and PVE with isolated large vegetations (>15 mm) and no other indications for surgery.
9) Aortic or mitral NVE and PVE with isolated very large vegetations (>30 mm).
Decision for surgery in patients with large vegetations (>15 mm) can be difficult and requires a careful individual approach.
Surgical treatment may also be considered after CNS embolism (including transient ischemic attack or asymptomatic embolism) as long as intracranial hemorrhage has been excluded, the patient is not in a comatose state, stroke has not caused very severe CNS damage, and no other contraindications to surgery are present. The risk of an embolic event is highest before the start of antimicrobial therapy and in the early days of treatment and decreases significantly after 2 weeks of therapy. Head CT or MRI should be conducted in every patient with neurologic complications. Indications for surgery in such patients include severe heart failure, uncontrolled sepsis, infection not responding to antimicrobial therapy, presence of an abscess, or persistence of a high embolic risk. Surgery using a cardiopulmonary bypass within the first 30 days of stroke is associated with a high risk of complications.
Treatment of CDRIE: Prolonged antimicrobial treatment (initially empiric treatment, optimally using an antistaphylococcal agent [vancomycin, given the high resistance rates], followed by targeted treatment based on susceptibility testing) and complete hardware removal is generally recommended.Evidence 3 Strong recommendation (benefits clearly outweigh downsides; right action for all or almost all patients). Low Quality of Evidence (low confidence that we know true effects of the intervention). Quality of Evidence lowered due to the observational nature of data. Le KY, Sohail MR, Friedman PA, et al; Mayo Cardiovascular Infections Study Group. Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. Heart Rhythm. 2011 Nov;8(11):1678-85. doi: 10.1016/j.hrthm.2011.05.015. Epub 2011 May 27. PubMed PMID: 21699855. A center capable of performing percutaneous removal of the implanted device including leads should be involved in such cases. In patients with vegetations >20 mm, surgical treatment should be considered. Given the risk of reinfection, indications for reimplantation of devices should be evaluated. If the patient is clinically stable, blood cultures should be negative for a minimum of 72 hours while antimicrobial therapy is continued. If the patient is dependent on the device, a temporary electrode should be implanted contralaterally. In case of evidence of remaining valvular infection, implantation should be delayed for 14 days.
Treatment of IE in IV drug abusers: Valve replacement is rarely recommended because substance dependence results in frequent recurrences of IE in this group of patients. Surgery may be considered in those with bacteremia persisting >7 days in spite of adequate antimicrobial treatment, fungal infections, right ventricular heart failure refractory to treatment, or those with persisting large (>20 mm) vegetations with recurrent pulmonary embolism.
Duration of therapy varies based on operative tissue cultures when surgery is pursued. In patients with negative operative tissue cultures, the first day of negative blood cultures on antimicrobial treatment is the first day of targeted therapy. In patients with positive valve tissue cultures, a new postoperative complete course of antimicrobial treatment using agents to which the isolated organisms are susceptible is recommended (with the operative day considered as day 0).
The patient should be carefully monitored for cardiac and extracardiac complications, especially for embolic events. In particular, the following parameters should be monitored: temperature (febrile or afebrile), white blood cell counts, and biochemical markers associated with any potential drug toxicities (eg, renal function). Repeat blood cultures after 48 to 72 hours should be collected to evaluate treatment response. Serial physical examinations should also be conducted to evaluate for endocarditis-related complications and sequelae. In patients undergoing antimicrobial treatment, the severity of valvular disease and any indications for surgery should be evaluated. After completing treatment, perform follow-up TTE for functional and morphologic evaluation.
Regular clinical follow-up is recommended following the completion of initial therapy.
1. General preventative measures, such as maintenance of general oral and skin hygiene, avoiding body piercings and tattoos, and minimizing unnecessary IV catheterization and invasive procedures, are important.
2. Indications for antimicrobial prophylaxis: Indications for prophylaxis of IE have been narrowed over time. Prophylaxis is currently indicated only before dental procedures involving gingival or periapical instrumentation or perforation of the oral mucosa (dental extraction, periodontal procedures, root canal treatment, scaling, dental implants)Evidence 4 Weak recommendation (benefits likely outweigh downsides, but the balance is close or uncertain; an alternative course of action may be better for some patients). Moderate Quality of Evidence (moderate confidence that we know true effects of the intervention). Quality of Evidence lowered due to indirectness. Cahill TJ, Harrison JL, Jewell P, et al. Antibiotic prophylaxis for infective endocarditis: a systematic review and meta-analysis. Heart. 2017 Jun;103(12):937-944. doi: 10.1136/heartjnl-2015-309102. Epub 2017 Feb 17. Review. PubMed PMID: 28213367. and only in in the following specific circumstances:
1) Prosthetic valve (including transcatheter valve replacement) or history of valve repair using prosthetic materials.
2) History of IE.
3) Congenital heart disease (cyanotic; up to 6 months after complete surgical or percutaneous repair of congenital heart disease using prosthetic materials; residual regurgitation or leak in the area of surgical or transcatheter implantation of prosthetic material).
4) Cardiac transplant patients with a structurally abnormal valve (as per the American Heart Association/American Society of Cardiology recommendations).
3. Recommended antimicrobial agents (a single dose 30-60 minutes before the procedure):
1) Patients with no allergy to penicillin: Oral or IV amoxicillin or ampicillin 2 g in adults or 50 mg/kg in children. Alternative agents are IV cefazolin or ceftriaxone 1 g in adults or 50 mg/kg in children.
2) Patients with allergy to penicillin: Oral or IV clindamycin 600 mg in adults or 20 mg/kg in children.
Tables and FiguresTop
1) Microorganisms demonstrated by culture or on histologic examination of a vegetation, a vegetation that has embolized, or an intracardiac abscess specimen; or
2) Pathologic lesions; vegetation or intracardiac abscess confirmed by histologic examination showing active endocarditis.
1) Blood cultures positive for IE:
a) Typical microorganisms consistent with IE from 2 separate blood cultures: Viridans-group streptococci, Streptococcus gallolyticus (formerly bovis), HACEK group, Staphylococcus aureus; or community-acquired enterococci in the absence of a primary focus; or
b) Microorganisms consistent with IE from persistently positive blood cultures: ≥2 positive blood cultures of samples drawn >12 h apart or all of 3 or a majority of ≥4 separate cultures of blood (with first and last samples drawn ≥1 h apart); or
c) Single positive blood culture for Coxiella burnetii or phase I IgG antibody titer >1:800.
2) Imaging studies positive for IE:
a) Echocardiography positive for IE: Vegetation; abscess, pseudoaneurysm, intracardiac fistula; valvular perforation or aneurysm; new partial dehiscence of a prosthetic valve.
b) Abnormal activity around the site of prosthetic valve implantation detected by 18F-FDG PET/CT (only if the prosthesis was implanted for >3 months) or radiolabeled leukocyte SPECT/CT.
c) Definite paravalvular lesions on cardiac CT.
1) Predisposition, such as predisposing heart condition or injection drug use.
2) Fever defined as temperature >38 degrees Celsius.
3) Vascular phenomena (including those detected by imaging only): Major arterial emboli, septic pulmonary infarcts, infectious (mycotic) aneurysm, intracranial hemorrhage, conjunctival hemorrhages, and Janeway lesions.
4) Immunologic phenomena: Glomerulonephritis, Osler nodes, Roth spots, and rheumatoid factor.
5) Microbiological evidence: Positive blood culture but not meeting a major criterion as noted above or serologic evidence of active infection with an organism consistent with IE.
Definite IE: 2 major criteria; 1 major criterion and 3 minor criteria; or 5 minor criteria.
Possible IE: 1 major criterion and 1 minor criterion; or 3 minor criteria.
1) Firm alternative diagnosis; or
2) Resolution of symptoms suggesting IE with antibiotic therapy for ≤4 days; or
3) No pathologic evidence of IE at surgery or autopsy with antibiotic therapy for ≤4 days; or
4) Not fulfilling the criteria for possible IE, as defined above.
Based on Eur Heart J. 2015;36(44):3075-3128.
18F-FDG PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed tomography; CT, computed tomography; HACEK, Haemophilus spp, Aggregatibacter spp, Cardiobacterium hominis, Eikenella corrodens, Kingella spp; IE, infective endocarditis; SPECT, single-photon emission computed tomography.
– Amoxicillin (or ampicillin) 200 mg/kg/d IV in 4-6 divided doses for 4-6 weeksa + gentamicinb 3 mg/kg/d IV or IM as single dose for 2-6 weeks; or
– Ampicillin 200 mg/kg/d IV in 4-6 divided doses for 6 weeks + ceftriaxone 4 g/d IV or IM in 2 divided doses for 6 weeksc; or
– Vancomycin 30 mg/kg/d in 2 divided doses for 6 weeks + gentamicinb 3 mg/kg IV as single dose for 6 weeks
– Resistance due to beta-lactamase production: Ampicillin/sulbactam or amoxicillin/clavulanic acid
– Resistance caused by penicillin-binding proteins: Regimen with vancomycin
Multidrug-resistant strains (resistance to aminoglycosides, beta-lactams, and vancomycin)d
– Daptomycin 10 mg/kg/d + ampicillin 200 mg/kg/d IV in 4-6 doses for ≥8 weeks; or
– Linezolid 600 mg IV or po bid for ≥8 weeks; or
– Quinupristin/dalfopristin 7.5 mg/kg tid for ≥8 weeks
Third-generation cephalosporin (eg, ceftriaxone 2 g/d for 4 weeks in NVE or 6 weeks in PVE); non-beta-lactamase–producing strains: ampicillin 12 g/d IV in 4 or 6 divided doses combined with gentamicin 3 mg/kg/d in 2 or 3 divided doses for 4-6 weeks
Doxycycline 200 mg/d + trimethoprim/sulfamethoxazole 960 mg bid + rifampin 300-600 mg/d for ≥3-6 months po; in the first few weeks you may add streptomycin 15 mg/kg/d in 2 divided doses
Doxycycline 200 mg/d + hydroxychloroquine 200-600 mg/d PO (regimen preferred over doxycycline alone) for >18 months
Doxycycline 100 mg PO bid for 4 weeks + gentamicin 3 mg/kg/d IV for 2 weeks
Levofloxacin 500 mg IV or PO bid for ≥6 weeks or clarithromycin 500 mg bid IV for 2 weeks, then PO for 4 weeks + rifampin 300-1200 mg for 6 weeks
Levofloxacin 500 mg IV or PO bid for ≥6 months
Doxycycline 200 mg/d + hydroxychloroquined 200-600 mg/d PO (regimen preferred over doxycycline alone) for ≥18 months
a Six-week treatment is recommended in patients with symptoms persisting for >3 months and in those with a prosthetic valve.
b Once a week monitor renal function and serum levels of gentamicin. The trough level should be <1 mg/L and level 1 hour after IV dose should be 10-12 mg/L.
c Regimen recommended in Enterococcus faecalis infection. It is the treatment of choice for aminoglycoside-resistant E faecalis species. Ineffective for Enterococcus faecium.
d Cooperation with an infectious disease specialist is essential.
Based on Eur Heart J. 2015;36(44):3075-3128.
bid, 2 times a day; HACEK, Haemophilus spp, Aggregatibacter spp, Cardiobacterium hominis, Eikenella corrodens, Kingella spp; IM, intramuscular; IV, intravenous; NVE, native valve endocarditis; PO, oral; PVE, prosthetic valve endocarditis; tid, 3 times a day.
Figure 3.10-1. Empiric antibiotic treatment for infective endocarditis before pathogen identification and in the case of negative cultures. Based on Eur Heart J. 2015;36(44):3075-3128.
Figure 3.10-2. Infective endocarditis caused by oral streptococci or Streptococcus gallolyticus group: targeted antibiotic treatment. Based on Eur Heart J. 2015;36(44):3075-3128.
Figure 3.10-3. Infective endocarditis caused by staphylococci: targeted antibiotic treatment. Based on Eur Heart J. 2015;36(44):3075-3128.